Nonsmall Cell Lung Cancer Therapy: Insight into Multitargeted Small-Molecule Growth Factor Receptor Inhibitors

Table 1

GFR targeted monoclonal antibodies (mAbs) for NSCLC therapy.

mAb name	Targeted GFR	Source	Current developed phase	Ongoing trial^a
Cetuximab	EGFR	Chimeric	III	NCT00408499; NCT00397384; NCT00946712; NCT00533949; NCT00368992; NCT01059188; NCT00867009; NCT00842712
Cixutumumab	IGF-1R	Human	I/II	NCT00955305; NCT01232452; NCT01263782; NCT00887159
EMD 72000 (Matuzumab)	EGFR	Humanized from mouse	II	—
Figitumumab (CP-751,871)	IGF-1R	Human	II	NCT00728390
Ganitumab (AMG 479)	IGF-1R	Human	I	NCT01327612
Necitumumab (IMC-11F8)	EGRF	Human	III	NCT00982111; NCT00981058; NCT01769391
Nimotuzumab	EGFR	Humanized from mouse	II	NCT01498562; NCT01393080
Olaratumab (IMC-3G3/LY3012207)	PDGFR-𝛼	Human	II	NCT00918203
Panitumumab	EGFR	Human	I	NCT00979212; NCT01042288; NCT01038037
Ramucirumab (IMC-1121B)	VEGF-2	Human	III	NCT01160744; NCT01168973; NCT01703091
Trastuzumab	HER-2	Humanized from mouse	II	NCT00847366; NCT01148849

^ahttp://www.clinicaltrial.gov/, access date March 16, 2013.